The therapeutic focus of Antistax (dry extract of Red Vine leaves) is centered on providing symptomatic support for mild-to-moderate venous circulatory issues. The preparation is considered relevant for managing symptoms associated with chronic venous disease and insufficiency.

The medicine is used to help address symptom clusters that may become intense or disruptive, specifically: heavy and tired legs, the sensation of tension, and minor leg swelling (edema). It is often applied when symptoms intensify due to lifestyle factors, such as prolonged periods of standing or immobility.

“It helps patients cope more steadily with these recurring episodes of physical discomfort.”

This therapy supports patients by easing the overall symptom load and contributing to improved comfort during symptomatic periods. It is commonly used across conditions presenting with symptomatic discomfort where additional supportive assistance is needed.

---

Quick Fact: Relief for Venous Fatigue Antistax is typically used to manage the feeling of tired legs and associated symptoms that interfere with daily functioning, particularly in adults.

The eligibility for using Antistax (Red Vine leaf extract) is strictly defined by regulatory guidelines, focusing on age and specific health statuses. This medicine is generally intended for use only in adults.

Official Eligibility and Contraindications

Classification	Population or Condition	Status Defined by Regulators
Allowed	Adults (18 years and older)	Approved for use
Contraindicated	Patients with Hypersensitivity	Must not use (Absolute prohibition)

Restricted and Not Recommended Populations

Certain groups should not use Antistax due to a lack of sufficient data, as stated in official product labeling:

• Children and Adolescents: Use in individuals under 18 years of age is not recommended because safety data are not available for the pediatric population.
• Pregnancy and Lactation: Use is not recommended during pregnancy or while breastfeeding because safety has not been established in these physiological states.

Patients are officially advised to consult a medical professional immediately if severe symptoms—such as sudden swelling, severe pain, or signs of underlying cardiac or renal insufficiency—appear, as these may require alternative medical attention.

The official regulatory documentation for Antistax (dry extract of Red Vine leaves, Vitis viniferae folium) establishes a specific interaction profile defined by the absence of officially documented interactions. The European Medicines Agency (EMA) Community herbal monograph and related regulatory summaries contain no explicit listings of drug-drug, drug-food, or other substance interactions for this product.

Interaction Profile Status	Official Regulatory Finding
Specific Interacting Medicines	None documented in official labeling.
Pharmacokinetic Interactions	No effects on metabolic enzymes (e.g., CYP) or drug transporters are specified.
Timing-Based Rules	No mandatory separation rules for administration are specified.
Interaction Restrictions	No formal restrictions or prohibited combinations are listed.

This profile confirms that no specific interaction mechanisms—such as those mediated by hepatic metabolic enzymes or drug transporters—have been officially identified or require caution. Therefore, the labeling contains no formal warnings regarding co-administration with other prescription medicines, over-the-counter products, or common dietary supplements. Furthermore, the official prescribing information does not list any population-specific interaction considerations, and there are no documented constraints concerning the simultaneous use of food or alcohol. The absence of specific warnings means the regulatory text does not mandate any timing separation for administration relative to other substances.

The active fraction, a standardized Vitis vinifera leaf extract (AS195), selectively accumulates in the vascular endothelium of the peripheral circulation, specifically the venous intima.

At the molecular level, its components, primarily polyphenols, function as inhibitors of oxidative stress by reducing the concentration of reactive oxygen species (ROS). This interaction preserves nitric oxide (NO) bioavailability. Concurrently, the extract modulates the activity of endothelial nitric oxide synthase (eNOS) by promoting its phosphorylation at the serine 1177 residue, thus acting as an indirect activator to increase NO generation in endothelial cells.

Downstream, the preserved NO signaling pathway mediates relaxation of vascular smooth muscle cells, resulting in a systemic modulation of peripheral vascular tone. Furthermore, the extract interacts with inflammatory cascades, including the nuclear factor-kappa B (NF-κB) pathway, to modulate pro-inflammatory mediator expression, leading to the preservation of endothelial barrier integrity and reduced microvascular permeability. These combined actions result in the physiological consequences of reduced transmural fluid filtration across the vessel wall and enhanced microcirculation.

Official Administration Guidelines for Antistax (Red Vine Leaf Extract)

The official instructions detail the precise administration of Antistax, which contains a dry extract of red vine leaves (AS 195).

Administration Scope	Official Instruction
Route of Administration	Oral (by mouth)
Dosage Form	Film-coated tablet (typically 360 mg strength)
Standard Dosing	One tablet daily
Dose Adjustment	The dose may be increased to two tablets (720 mg) daily, if necessary.

Procedural Rules

The medicine is designed for a once-daily intake in adults, with specific instructions regarding timing and duration:

• Timing: The tablet should be taken in the morning. It is generally advised to take the tablet before a meal (e.g., before breakfast).
• Method: The film-coated tablet must be swallowed whole with water; it should not be chewed or crushed.
• Missed Dose: If a dose is missed, individuals should not take a double dose to compensate. The patient should resume the dosing schedule with the next planned dose.
• Duration: Continuous treatment is typically limited to a period of 12 weeks (3 months), as efficacy beyond this duration has not been studied in relevant trials.

Age Restriction

Use of this product cannot be recommended for the pediatric population, including children and adolescents under 18 years of age, due to a lack of sufficient data in this age group.

Research Evidence / Overview of Studies for Antistax

Research examining the dry extract of Red Vine leaves was conducted primarily in adults with mild-to-moderate Chronic Venous Insufficiency (CVI). The evidence base for this context is largely derived from Randomized Controlled Trials (RCTs). In these studies, the extract was evaluated in participants who were compared to a group receiving a placebo (an inactive substance).

The studies focused on outcomes related to physical discomfort in the lower legs. Researchers applied studies examining patient-reported experiences, as well as objective measures like leg volume. Findings describe patterns observed in the trials, where measurements of lower leg fluid volume were observed to change during the study period. Furthermore, patient-reported outcomes describing symptom intensity were also monitored during the trials. Studies contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

---

Evidence for Traditional Use in Minor Circulatory Discomfort

The extract is indicated for minor, general circulatory discomforts in the legs and is also categorized under the regulatory path of "Traditional Use." This classification is based on documentation of historical use and patient experiences, rather than solely relying on recent high-level clinical trials. This evidence helped contextualize how patients reported their perceived discomfort over the historical period used for regulatory classification.

---

Study Design and Limitations

Follow-up durations for the majority of high-quality clinical research have been limited, typically observing responses over defined time intervals, usually between 6 and 12 weeks. This focus on short-term symptom patterns indicates that long-term effects are not fully established.

The results apply only to the populations studied, which were primarily adults with mild-to-moderate symptoms of CVI. Data for certain groups remain insufficient; specifically, there are few data available for groups such as children and adolescents. Comparative evidence is also lacking regarding the extract and other management strategies.

Common questions about Antistax (FAQ)

Q: Does Antistax cure the underlying problem, or just help with the symptoms?

According to official product information, Antistax is indicated for the symptomatic relief of minor circulatory disturbances in the legs, which are often related to chronic venous insufficiency (CVI). Regulatory documents state that its purpose is to help ease discomfort such as leg heaviness and swelling, but they do not claim that it cures the underlying condition.

Q: Is it normal to feel a tingling sensation when you first start taking Antistax?

Official product documentation detailing known side effects does not list a common or expected 'tingling sensation' upon starting treatment. Reported side effects primarily relate to the gastrointestinal system, and less frequently, to skin reactions like itching or hives. If unexpected or persistent symptoms occur, official guidance suggests seeking medical evaluation.

Q: Are the Antistax tablets and the Antistax cooling gel used for the same thing?

Antistax tablets are classified as an oral herbal medicine taken by mouth to provide systemic relief for symptoms of venous insufficiency. Topical products, such as gels or creams, are often classified differently (e.g., as cosmetics or medical devices) and are typically intended for localized relief of discomfort and heaviness on the skin.

Q: Is there scientific proof or clinical research that backs up the effectiveness of Antistax?

Official authorization is supported by clinical data from Randomized Controlled Trials (RCTs) involving adults with chronic venous insufficiency (CVI). These studies assessed changes in objective measures, such as leg fluid volume, and evaluated patient-reported symptoms, confirming the product's use for symptomatic relief.

Q: Does Antistax cause weight gain or weight loss?

The official product documentation on known side effects (adverse reactions) does not list weight gain or weight loss. Therefore, changes in weight are not listed among the known or commonly reported adverse reactions for Antistax.

Q: Can I take Antistax if I am already taking blood thinners?

Official labeling states that no specific drug-drug interaction studies have been conducted. Official guidance suggests that individuals currently taking other medications, especially blood thinners, should consult a healthcare professional before starting Antistax.

Q: Are there any specific foods or drinks I should avoid while on Antistax?

Official regulatory texts do not list any specific foods or drinks that must be strictly avoided while taking Antistax. The tablet is advised to be taken in the morning before a meal with water.

Q: What is the source of the red vine leaf extract used in Antistax?

The active substance is the dry extract of Red Vine leaves, sourced from the common Red Vine plant, Vitis vinifera L. This extract is standardized to ensure a consistent profile of specific active flavonoids in the medicine.

Q: Does stopping Antistax suddenly cause any rebound effects?

Official documentation does not list any rebound phenomena or withdrawal symptoms upon sudden cessation of Antistax use. As a symptomatic relief medication, it is not associated with the complex withdrawal effects observed with certain prescription drugs.

Q: Can people with liver or kidney problems safely use Antistax?

Official documentation does not contain specific warnings, precautions, or dosage adjustments for individuals with pre-existing liver or kidney impairment. Official guidance suggests that individuals with pre-existing conditions should consult a healthcare professional before starting any new medication.

Q: Are there any potential interactions between Antistax and common cold/flu remedies?

Official regulatory documentation states that no formal warnings are listed regarding co-administration with other prescription or over-the-counter medicines, including cold and flu remedies. This is because no specific interactions have been identified in the official review process.

Q: What are the long-term safety data regarding the use of Antistax?

Regulatory documents note that efficacy has primarily been studied up to 12 weeks. The product information often advises consulting a healthcare professional if symptoms persist beyond this period, as long-term effects beyond 12 weeks have not been fully established in relevant trials.

Q: Can I use the Antistax cooling gel at the same time as taking the tablets?

Official regulatory documents do not prohibit the simultaneous use of the oral tablets and the topical gel or cream. This is because no systemic interactions are expected between the orally absorbed medicine and an external application.

Q: Will Antistax help prevent future vein problems?

Antistax is officially indicated for the symptomatic relief of existing venous circulatory disturbances. Regulatory indications do not confirm its use as a preventative measure against the future development of vein problems.

Q: What happens if I take more than the recommended dose of Antistax?

Official documentation states that if more than the recommended amount is taken, a medical professional should be consulted immediately for guidance.

How to Store and Dispose of Antistax?

Official regulatory documents define strict conditions for the storage and final disposal of Antistax film-coated tablets.

Storage Conditions

Antistax must be stored in the original container and kept at a temperature below 30 C (eighty-six degrees Fahrenheit). The tablets must be protected from light and moisture to maintain product stability. As a mandatory requirement for all medicines, the product must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Antistax must not be thrown away in household garbage or disposed of via wastewater (flushed down the toilet). To ensure environmental protection, patients are instructed to ask their pharmacist for guidance on how to safely dispose of medicines no longer required.